AR020062A1 - Una composicion farmaceutica solida o semisolida para la liberacion sostenida de peptidos - Google Patents

Una composicion farmaceutica solida o semisolida para la liberacion sostenida de peptidos

Info

Publication number
AR020062A1
AR020062A1 ARP990101275A ARP990101275A AR020062A1 AR 020062 A1 AR020062 A1 AR 020062A1 AR P990101275 A ARP990101275 A AR P990101275A AR P990101275 A ARP990101275 A AR P990101275A AR 020062 A1 AR020062 A1 AR 020062A1
Authority
AR
Argentina
Prior art keywords
solid
pharmaceutical composition
peptides
sustained release
semisolid pharmaceutical
Prior art date
Application number
ARP990101275A
Other languages
English (en)
Original Assignee
Scient S C R A S Soc De Conseils De Rech S Et D Applic S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scient S C R A S Soc De Conseils De Rech S Et D Applic S filed Critical Scient S C R A S Soc De Conseils De Rech S Et D Applic S
Publication of AR020062A1 publication Critical patent/AR020062A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una composicion farmacéutica solida o semisolida que contiene una sal de péptido soluble gelificable de alta área específica superficial. Esta composiciontambién puede comprender un excipiente y/o agua. Una vez inyectada en un paciente, la composicion se gelifica y libera la sal de péptido durante un períodoprolongado de al menos 15 días.
ARP990101275A 1998-03-25 1999-03-23 Una composicion farmaceutica solida o semisolida para la liberacion sostenida de peptidos AR020062A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9803667A FR2776520B1 (fr) 1998-03-25 1998-03-25 Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation

Publications (1)

Publication Number Publication Date
AR020062A1 true AR020062A1 (es) 2002-04-10

Family

ID=9524472

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101275A AR020062A1 (es) 1998-03-25 1999-03-23 Una composicion farmaceutica solida o semisolida para la liberacion sostenida de peptidos

Country Status (19)

Country Link
US (1) US6503534B1 (es)
EP (1) EP1066049B1 (es)
JP (1) JP4162381B2 (es)
AR (1) AR020062A1 (es)
AT (1) ATE241377T1 (es)
AU (1) AU756148B2 (es)
CA (1) CA2324901C (es)
CZ (1) CZ298941B6 (es)
DE (1) DE69908326T2 (es)
DK (1) DK1066049T3 (es)
ES (1) ES2200507T3 (es)
FR (1) FR2776520B1 (es)
HU (1) HU228903B1 (es)
IL (2) IL138533A0 (es)
NO (1) NO324621B1 (es)
PL (1) PL197775B1 (es)
PT (1) PT1066049E (es)
RU (1) RU2224538C2 (es)
WO (1) WO1999048517A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
NZ538928A (en) * 2002-09-27 2006-10-27 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release of active ingredient, and method for the production thereof
WO2004087102A2 (en) * 2003-03-26 2004-10-14 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area
EP3025722B1 (en) 2003-10-03 2020-05-27 Thorn BioScience, LLC Process for the synchronization of ovulation for timed breeding without heat detection
CA2550695A1 (en) * 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Glp-1 pharmaceutical compositions
US20090023644A1 (en) * 2004-01-13 2009-01-22 Southard Jeffery L Methods of using cgrp for cardiovascular and renal indications
CA2552677A1 (en) * 2004-01-13 2005-07-28 Vasogenix Pharmaceuticals, Inc. Controlled release cgrp delivery composition for cardiovascular and renal indications
TW200538148A (en) * 2004-01-13 2005-12-01 Vasogenix Pharmaceuticals Inc Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP1912724A2 (en) * 2005-07-28 2008-04-23 Global Research Technologies, LLC Removal of carbon dioxide from air
GB0517627D0 (en) 2005-08-30 2005-10-05 Tyco Electronics Ltd Uk Bus-bar and connector
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20070219811A1 (en) * 2006-03-16 2007-09-20 Kim John S Method for using an internet-based CRM application to create an on-line leads marketplace
ES2447516T3 (es) * 2006-12-21 2014-03-12 Stryker Corporation Formulaciones de liberación sostenida que comprenden cristales BMP-7
EP2142207A4 (en) * 2007-04-04 2013-01-16 Theratechnologies Inc PHARMACEUTICAL FORMULATIONS OF GHRH MOLECULES
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
CA2953975C (en) 2008-06-27 2019-11-26 Duke University Therapeutic agents comprising elastin-like peptides
ES2661240T3 (es) 2009-04-23 2018-03-28 Jbs United Animal Health Ii Llc Método y composición para sincronizar el momento de inseminación
KR101795643B1 (ko) 2009-05-01 2017-11-09 훼링 비.브이. 전립선암 치료용 조성물
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2464370B1 (en) 2009-08-14 2017-03-29 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
TWI536999B (zh) * 2010-01-13 2016-06-11 艾普森藥品公司 製備持續釋放生長激素抑制素類似物之醫藥組成物之方法
HUE031113T2 (en) 2010-10-27 2017-06-28 Ferring Bv Procedure for the preparation of Degarelix and its intermediates
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
CN107569456A (zh) 2012-06-01 2018-01-12 辉凌公司 制造地加瑞克
ES2808409T3 (es) 2012-11-28 2021-02-26 United Ah Ii Llc Método para sincronizar el tiempo de inseminación en cerdas primerizas
EP2823808A1 (en) 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
EP2910255A1 (en) * 2014-02-19 2015-08-26 MedSkin Solutions Dr. Suwelack AG Methods for the production of biopolymers with defined average molecular weight
TW201625218A (zh) * 2014-04-18 2016-07-16 Ｊｂｓ聯合動物保健有限責任公司 製造含ｇｎｒｈ凝膠之方法
EP3139949B1 (en) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
US10688156B2 (en) 2015-02-09 2020-06-23 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
WO2020170185A1 (en) * 2019-02-21 2020-08-27 Dr. Reddy’S Laboratories Limited Substantially pure lanreotide or its salt & process thereof
GR1009814B (el) * 2019-07-29 2020-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης
CN110577567A (zh) * 2019-09-03 2019-12-17 杭州诺泰澳赛诺医药技术开发有限公司 一种制备高比表面积活性多肽或蛋白的方法
CN118302211A (zh) * 2021-11-22 2024-07-05 Specgx有限责任公司 可注射缓释药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013285A1 (en) * 1989-05-01 1990-11-15 Enzytech, Inc. Process for producing small particles of biologically active molecules
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions

Also Published As

Publication number Publication date
EP1066049B1 (fr) 2003-05-28
PL197775B1 (pl) 2008-04-30
DE69908326D1 (de) 2003-07-03
PL343005A1 (en) 2001-07-30
HUP0101545A3 (en) 2001-12-28
FR2776520A1 (fr) 1999-10-01
CA2324901C (fr) 2012-01-24
JP4162381B2 (ja) 2008-10-08
FR2776520B1 (fr) 2000-05-05
AU756148B2 (en) 2003-01-02
DE69908326T2 (de) 2004-03-25
US6503534B1 (en) 2003-01-07
CA2324901A1 (fr) 1999-09-30
RU2224538C2 (ru) 2004-02-27
CZ20003432A3 (cs) 2001-02-14
ATE241377T1 (de) 2003-06-15
PT1066049E (pt) 2003-10-31
NO20004741L (no) 2000-11-22
IL138533A (en) 2006-12-31
NO20004741D0 (no) 2000-09-22
IL138533A0 (en) 2001-10-31
ES2200507T3 (es) 2004-03-01
WO1999048517A1 (fr) 1999-09-30
AU2938499A (en) 1999-10-18
NO324621B1 (no) 2007-11-26
HUP0101545A1 (hu) 2001-11-28
DK1066049T3 (da) 2003-09-29
HU228903B1 (en) 2013-06-28
EP1066049A1 (fr) 2001-01-10
CZ298941B6 (cs) 2008-03-19
JP2002507578A (ja) 2002-03-12

Similar Documents

Publication Publication Date Title
AR020062A1 (es) Una composicion farmaceutica solida o semisolida para la liberacion sostenida de peptidos
ES2050070B1 (es) Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica.
BR0008405A (pt) Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
GT199800126A (es) Terapia de combinacion.
HUP0301842A2 (hu) Laktám vegyület, a vegyületet tartalmazó gyógyszerkészítmény és alkalmazása gyógyszerkészítmény elżállítására
ATE493998T1 (de) Pharmazeutische zusammensetzung mit einem exendin-4-peptid
ES8802526A1 (es) Procedimiento para preparar peptidos trifluormetilcetona-sustituidos
BR9406720A (pt) Utilização de um adenovírus recombinante de origem animal adenovírus recombinante de origem animal e composição farmacêutica compreendendo um ou vários adenovírus
TR199902071T2 (xx) Heterosiklik bile�ikler ve bunlar�n �-amilioid peptidinin inhibisyonunda kullan�m�
BR9713866A (pt) Composição farmacéutica
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
TR199802534T2 (xx) Leptin (OB Protein) fragmanlar�
ITFI990258A0 (it) Protesi dentale con mezzi per il rilascio di farmaci o fattori specifi ci atti ad impedire l'insorgenza di infezioni e/o promuovere la cresci
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
SE9402880D0 (sv) New peptide derivatives
FR2696925B3 (fr) Nécessaire de chirurgie orthopédique destiné à réaliser l'ancrage de la partie osseuse d'un ligament dans un tunnel osseux.
UY27373A1 (es) Formulaciones de interferón beta-humano
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
ES2154761T3 (es) Mejora de la tolerancia de beta-aminoacidos farmaceuticamente activos.
GT199900171A (es) Concentrado oral de sertralina.
BR0008385A (pt) Laxantes efervescentes
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.
IT1291895B1 (it) Preparazione farmaceutica fluida a base di nimesulide per uso orale e rinofaringeo

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FC Refusal